Individuals with cystic fibrosis (CF) aged 12 years and older on the CF transmembrane conductance regulator (CFTR) modulator drug Trikafta® did not experience a decline in their lung function when they ceased taking hypertonic saline or dornase alfa, according to a news release. 

The properties of Trikafta became apparent after a 6-week study funded by the Cystic Fibrosis Foundation. The study was led by scientists from the University of Washington, Seattle Children’s Research Institute, and University Hospitals Cleveland Medical Center. The scientists were able to conduct the study collectively via the Cystic Fibrosis Therapeutics Development Network. 

The study found that patients with CF were able to cease taking 1 of 2 commonly prescribed CF medications without any negative implications to their health. When participants with CF were on Trikafta, they demonstrated relatively good lung function, even after they stopped taking either of the inhaled therapies. In addition, patients neither experienced worsening of respiratory symptoms, nor did they require additional antibiotics throughout the 6-week study period. 

“The Simplify clinical study is the first to evaluate the potential for stopping certain daily medications while on Trikafta, and we hope it will provide important information to enable discussions between people with cystic fibrosis and their care providers,” said Nicole Hamblett, PhD, professor of pediatrics from the University of Washington and Seattle Children’s Research Institute. 

Read more about CF etiology 

Patients with CF are typically prescribed a number of medications and supplements that require regular intake to control their disease. Studies indicate that patients spend an average of 2 to 3 hours every day managing their care. 

Despite the promising findings of this clinical trial, experts still strongly advise patients with CF to consult their physician prior to stopping any medications. 


Simplify study indicates potential to reduce medication burden for people with CF taking Trikafta. News release. Cystic Fibrosis Foundation; November 4, 2022.